Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(2):147–151. doi: 10.1054/bjoc.2001.1871

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

S I Helle 1, J Geisler 1, G B Anker 1, B Leirvaag 1, J M P Holly 2, P E Lønning 1
PMCID: PMC2364048  PMID: 11461068

Abstract

Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5 mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2–3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2 and IGFBP-3 were measured by radioimmuno-/immunoradiometric-assays. All samples were subjected to Western ligand blotting as well as immunoblotting for IGFBP-3. We observed a significant decrease (percentage of pretreatment levels with 95 confidence intervals of the mean) in IGF-I [2 weeks 63% (49–79); 1 month 56% (44–73); 2–3 months 66% (53–82)], IGF-II [2 weeks 67% (56–80); 1 month 60% (52–68); 2–3 months 64% (55–75)], free IGF-I [2 weeks 29% (19–42); 1 month 25% (18–36); 2–3 months 31% (21–46)], IGFBP-2 [2 weeks 53% (18–156); 1 month 69% (61–78); 2–3 months 66% (57–78)], IGFBP-3 [2 weeks 74% (63–85); 1 month 69% (62–76); 2–3 months 71% (63–80)], as well as IGFBP-3 protease activity [2 weeks 71% (54–95); 1 month 78% (64–94); 2–3 months 71% (54–93)]. Contrary, the plasma levels (percentage of pretreatment levels with 95 confidence intervals of the mean) of IGFBP-1 [2 weeks 250% (127–495); 1 month 173% (138–542); 2–3 months 273% (146–510)] and IGFBP-4 [2 weeks 146% (112–192); 1 month 140% (116–169); 2–3 months 150% (114–198)] increased significantly. While this study confirms previous observations during treatment with oral oestrogens in substitution doses, the reduction in plasma IGF-II, free IGF-I, IGFBP-2 and -3 are all novel findings. A profound decrease in free IGF-I suggests a reduced bioavailability of IGFs from plasma to the tissues. These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: high dose oestrogens, breast cancer therapy, IGF-system

Full Text

The Full Text of this article is available as a PDF (86.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arteaga C. L., Kitten L. J., Coronado E. B., Jacobs S., Kull F. C., Jr, Allred D. C., Osborne C. K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov;84(5):1418–1423. doi: 10.1172/JCI114315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bereket A., Lang C. H., Blethen S. L., Fan J., Frost R. A., Wilson T. A. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab. 1995 Aug;80(8):2282–2288. doi: 10.1210/jcem.80.8.7543110. [DOI] [PubMed] [Google Scholar]
  3. Bishop M. C., Selby C., Taylor M. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine. Br J Urol. 1985 Oct;57(5):542–547. doi: 10.1111/j.1464-410x.1985.tb05863.x. [DOI] [PubMed] [Google Scholar]
  4. Bowsher R. R., Lee W. H., Apathy J. M., O'Brien P. J., Ferguson A. L., Henry D. P. Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids. Endocrinology. 1991 Feb;128(2):805–814. doi: 10.1210/endo-128-2-805. [DOI] [PubMed] [Google Scholar]
  5. Carter A. C., Sedransk N., Kelley R. M., Ansfield F. J., Ravdin R. G., Talley R. W., Potter N. R. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA. 1977 May 9;237(19):2079–2078. [PubMed] [Google Scholar]
  6. Cohen P., Peehl D. M., Stamey T. A., Wilson K. F., Clemmons D. R., Rosenfeld R. G. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993 Apr;76(4):1031–1035. doi: 10.1210/jcem.76.4.7682560. [DOI] [PubMed] [Google Scholar]
  7. Colletti R. B., Roberts J. D., Devlin J. T., Copeland K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989 Apr 1;49(7):1882–1884. [PubMed] [Google Scholar]
  8. Cotterill A. M., Mendel P., Holly J. M., Timmins A. G., Camacho-Hübner C., Hughes S. C., Ross R. M., Blum W. F., Langford R. M. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clin Endocrinol (Oxf) 1996 Jan;44(1):91–101. doi: 10.1046/j.1365-2265.1996.649471.x. [DOI] [PubMed] [Google Scholar]
  9. Coulson V. J., Wass J. A., Abdulla A. F., Cotterill A. M., Holly J. M. Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul. 1991 Sep;1(3):119–124. [PubMed] [Google Scholar]
  10. Daughaday W. H., Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989 Feb;10(1):68–91. doi: 10.1210/edrv-10-1-68. [DOI] [PubMed] [Google Scholar]
  11. Dunn S. E., Ehrlich M., Sharp N. J., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J. C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998 Aug 1;58(15):3353–3361. [PubMed] [Google Scholar]
  12. Fex G., Adielsson G., Mattson W. Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol (Copenh) 1981 May;97(1):109–113. doi: 10.1530/acta.0.0970109. [DOI] [PubMed] [Google Scholar]
  13. Frost V. J., Helle S. I., Lønning P. E., van der Stappen J. W., Holly J. M. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab. 1996 Jun;81(6):2216–2221. doi: 10.1210/jcem.81.6.8964854. [DOI] [PubMed] [Google Scholar]
  14. Giudice L. C., Farrell E. M., Pham H., Lamson G., Rosenfeld R. G. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab. 1990 Oct;71(4):806–816. doi: 10.1210/jcem-71-4-806. [DOI] [PubMed] [Google Scholar]
  15. Haddow A., Watkinson J. M., Paterson E., Koller P. C. Influence of Synthetic Oestrogens on Advanced Malignant Disease. Br Med J. 1944 Sep 23;2(4368):393–398. doi: 10.1136/bmj.2.4368.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998 May 9;351(9113):1393–1396. doi: 10.1016/S0140-6736(97)10384-1. [DOI] [PubMed] [Google Scholar]
  17. Helle S. I., Anker G. B., Tally M., Hall K., Lønning P. E. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):167–171. doi: 10.1016/0960-0760(95)00257-x. [DOI] [PubMed] [Google Scholar]
  18. Helle S. I., Geisler J., Poulsen J. P., Hestdal K., Meadows K., Collins W., Tveit K. M., Holly J. M., Lønning P. E. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. Br J Cancer. 1998 Jul;78(1):14–20. doi: 10.1038/bjc.1998.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Helle S. I., Holly J. M., Tally M., Hall K., Vander Stappen J., Lønning P. E. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer. 1996 Aug 22;69(4):335–339. doi: 10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  20. Helle S. I., Omsjø I. H., Hughes S. C., Botta L., Hüls G., Holly J. M., Lønning P. E. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 1996 Dec;45(6):727–732. doi: 10.1046/j.1365-2265.1996.8610870.x. [DOI] [PubMed] [Google Scholar]
  21. Hossenlopp P., Seurin D., Segovia-Quinson B., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 1986 Apr;154(1):138–143. doi: 10.1016/0003-2697(86)90507-5. [DOI] [PubMed] [Google Scholar]
  22. Huynh H. T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 1993 Apr 15;53(8):1727–1730. [PubMed] [Google Scholar]
  23. Hwa V., Tomasini-Sprenger C., Bermejo A. L., Rosenfeld R. G., Plymate S. R. Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells. J Clin Endocrinol Metab. 1998 Dec;83(12):4355–4362. doi: 10.1210/jcem.83.12.5341. [DOI] [PubMed] [Google Scholar]
  24. Ingle J. N., Ahmann D. L., Green S. J., Edmonson J. H., Bisel H. F., Kvols L. K., Nichols W. C., Creagan E. T., Hahn R. G., Rubin J. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16–21. doi: 10.1056/NEJM198101013040104. [DOI] [PubMed] [Google Scholar]
  25. Jones J. I., Clemmons D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995 Feb;16(1):3–34. doi: 10.1210/edrv-16-1-3. [DOI] [PubMed] [Google Scholar]
  26. Kam G. Y., Leung K. C., Baxter R. C., Ho K. K. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918–1922. doi: 10.1210/jcem.85.5.6527. [DOI] [PubMed] [Google Scholar]
  27. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M. Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993 Jul;77(1):229–233. doi: 10.1210/jcem.77.1.7686915. [DOI] [PubMed] [Google Scholar]
  28. Karey K. P., Sirbasku D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988 Jul 15;48(14):4083–4092. [PubMed] [Google Scholar]
  29. Lassarre C., Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology. 1994 Mar;134(3):1254–1262. doi: 10.1210/endo.134.3.7509737. [DOI] [PubMed] [Google Scholar]
  30. Lee A. V., Darbre P., King R. J. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994 Mar;99(2):211–220. doi: 10.1016/0303-7207(94)90010-8. [DOI] [PubMed] [Google Scholar]
  31. Lee A. V., Weng C. N., Jackson J. G., Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol. 1997 Jan;152(1):39–47. doi: 10.1677/joe.0.1520039. [DOI] [PubMed] [Google Scholar]
  32. Lippman M., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976 Dec;36(12):4595–4601. [PubMed] [Google Scholar]
  33. Love R. R., Wiebe D. A., Newcomb P. A., Cameron L., Leventhal H., Jordan V. C., Feyzi J., DeMets D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991 Dec 1;115(11):860–864. doi: 10.7326/0003-4819-115-11-860. [DOI] [PubMed] [Google Scholar]
  34. Lønning P. E., Hall K., Aakvaag A., Lien E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992 Sep 1;52(17):4719–4723. [PubMed] [Google Scholar]
  35. Masamura S., Santner S. J., Heitjan D. F., Santen R. J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995 Oct;80(10):2918–2925. doi: 10.1210/jcem.80.10.7559875. [DOI] [PubMed] [Google Scholar]
  36. Molloy C. A., May F. E., Westley B. R. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 2000 Apr 28;275(17):12565–12571. doi: 10.1074/jbc.275.17.12565. [DOI] [PubMed] [Google Scholar]
  37. Müller H. L., Oh Y., Gargosky S. E., Lehrnbecher T., Hintz R. L., Rosenfeld R. G. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab. 1993 Nov;77(5):1113–1119. doi: 10.1210/jcem.77.5.7521338. [DOI] [PubMed] [Google Scholar]
  38. Peethambaram P. P., Ingle J. N., Suman V. J., Hartmann L. C., Loprinzi C. L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat. 1999 Mar;54(2):117–122. doi: 10.1023/a:1006185805079. [DOI] [PubMed] [Google Scholar]
  39. Pratt S. E., Pollak M. N. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 1993 Nov 1;53(21):5193–5198. [PubMed] [Google Scholar]
  40. Salahifar H., Baxter R. C., Martin J. L. Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1. Endocrinology. 2000 Sep;141(9):3104–3110. doi: 10.1210/endo.141.9.7684. [DOI] [PubMed] [Google Scholar]
  41. Stewart A. J., Johnson M. D., May F. E., Westley B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990 Dec 5;265(34):21172–21178. [PubMed] [Google Scholar]
  42. Weissberger A. J., Ho K. K., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):374–381. doi: 10.1210/jcem-72-2-374. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES